November 7, 2016
Amryt gets FDA's designation for orphan drug to treat acromegaly
Amryt has received orphan drug designation from U.S. Food and Drug Administration (FDA) for its drug compound…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
November 7, 2016
Richard Jones goes from Shield Therapeutics to Mereo as CFO
Mereo BioPharma has appointed Richard CM Jones as Chief Financial Officer
November 7, 2016
Celyad's NKR phase I trial shows encouraging results
The first data analysis of the NKR-2 Phase I trial, run by the Belgia’s biopharmaceutical company Celyad, shows encouraging results
November 7, 2016
Surgical Innovations buys Surgical Dynamic Limited
Surgical Innovations Group has completed the acquisition of the laparoscopic instruments …
November 7, 2016
Avacta names Prof. Gerard Evans to its Scientific Advisory Board
Professor Gerard Evan, FRS, has joined Scientific Advisory Board of Avacta Group, the developer of Affimer biotherapeutics and research reagents.
November 4, 2016
Drugmakers under fire for possible U.S. price fixing
Two prominent U.S. lawmakers on Thursday called on federal antitrust regulators to probe whether Sanofi SA, Eli Lilly and Co, Merck…
November 4, 2016
Genfit gets FDA’s IND clearance for PBC drug to go on with phase 2 study
The primary objective is to determine the effect of daily oral administration of elafibranor on serum alkaline phosphatase (ALP) in these patients, based on relative change versus placebo.
November 4, 2016
Lartruvo-soft tissue sarcoma drug to sell in U.S.
FDA granted accelerated approval to Lartruvo (olaratumab) injection, in combination with doxorubicin, for the treatment of adult patients…
November 4, 2016
Cardinal Health approves a regular quarterly dividend
Cardinal Health has announced on Thursday that the board of directors approved a regular quarterly dividend…
November 4, 2016
Gelesis weight loss capsules increase fullnes, study shows
Gelesis, focused on developing first-in-class products to safely induce weight loss and improve glycaemic control, has presented new data for its second product candidate, Gelesis200